This document discusses bracketing and matrixing designs for stability testing of new drug substances and products according to ICH Q1D guidelines. Bracketing design involves testing only the extremes of design factors like strength or container size, assuming stability of intermediates is represented by extremes. Matrixing design involves testing selected combinations of factors at each time point rather than all combinations at all time points. Both designs provide reduced testing compared to full design testing all samples at all time points, but require justification and carry potential risks of underestimating shelf life if variability is high.
IPQC cover the entire chain of operations from the receipt of raw material in the warehouse to the release of finished products from the warehouse for distribution and or sale. IPQC is a process where quality of a product is ensured that it meets the standard according to regulatory authority guidline.
IPQC cover the entire chain of operations from the receipt of raw material in the warehouse to the release of finished products from the warehouse for distribution and or sale. IPQC is a process where quality of a product is ensured that it meets the standard according to regulatory authority guidline.
IPQC?
Its Need
In-Process Quality Control tests for Tablets
Hardness
Friability
Thickness
Disintegration Time
Weight variation
Content uniformity
Dissolution test
Leakage testing for strip and blister packaging
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
Expiry date , calculation of yields, production record review, change controlSantosh kumar
The responsibility of the pharmaceutical manufacturer is that the drug product should have the stated potency and therapeutic effectiveness till the end of the shelf life of the product This shelf life should be based on t
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
QUALIFICATION & VALIDATION.Validation is an essential part of GMP, and an element of QA.Critical steps in the process need to be validated.Need for confidence that the product will consistently meet predetermined specifications and attributes.
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLCAnupriyaNR
Analytical method qualification consists of a simplified evaluation of a subset of validation characteristics with a goal to demonstrate that an analytical method is scientifically sound and suitable for its intended use. In contrast to validation, analytical method qualification is performed without predefined acceptability criteria. Qualification may be performed as a prerequisite to method validation, or when an assay for product knowledge has not yet been established as a test for a critical product quality attribute. Qualification of equipment is pre-requisite for validation of the process in which the equipment is being used. Many types of equipment have measuring devices on them. Calibration of measuring devices is a part of qualification. Calibration of measuring devices is important, as the data is often collected through them. If the data collected is not from measuring devices that have been calibrated, the data cannot be relied upon. Thus the whole validation exercise can be questioned.
Bracketing and matrixing designs (Q1D) AISSMS College Of PharmacyAISSMS
Read an interesting information about Bracketing and Matrixing designs for stability testing of new drug substances and products by AISSMS College Of Pharmacy.
IPQC?
Its Need
In-Process Quality Control tests for Tablets
Hardness
Friability
Thickness
Disintegration Time
Weight variation
Content uniformity
Dissolution test
Leakage testing for strip and blister packaging
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
Expiry date , calculation of yields, production record review, change controlSantosh kumar
The responsibility of the pharmaceutical manufacturer is that the drug product should have the stated potency and therapeutic effectiveness till the end of the shelf life of the product This shelf life should be based on t
This guideline is a revised of the ICHQ1A –stability data package for new drug substance /DRUG PRODUCT .The [urpose of guideline to define stability data package that sufficient for a registration application within the 3 regions of EU ,JAPAN & USA & to maintain the quality of drug products, in relation to safety , efficacy & acceptability throughout the propose shelf life.
QUALIFICATION & VALIDATION.Validation is an essential part of GMP, and an element of QA.Critical steps in the process need to be validated.Need for confidence that the product will consistently meet predetermined specifications and attributes.
QUALIFICATION OF UV-VISIBLE SPECTROPHOTOMETER, FTIR, DSC, HPLCAnupriyaNR
Analytical method qualification consists of a simplified evaluation of a subset of validation characteristics with a goal to demonstrate that an analytical method is scientifically sound and suitable for its intended use. In contrast to validation, analytical method qualification is performed without predefined acceptability criteria. Qualification may be performed as a prerequisite to method validation, or when an assay for product knowledge has not yet been established as a test for a critical product quality attribute. Qualification of equipment is pre-requisite for validation of the process in which the equipment is being used. Many types of equipment have measuring devices on them. Calibration of measuring devices is a part of qualification. Calibration of measuring devices is important, as the data is often collected through them. If the data collected is not from measuring devices that have been calibrated, the data cannot be relied upon. Thus the whole validation exercise can be questioned.
Bracketing and matrixing designs (Q1D) AISSMS College Of PharmacyAISSMS
Read an interesting information about Bracketing and Matrixing designs for stability testing of new drug substances and products by AISSMS College Of Pharmacy.
Shivam Dubey Pharmaceutics Assignment 03: ICH Guidelines On Drug StudiesMrHotmaster1
Sedatives & Hypnotics
Sedatives
➢ It is a drug that reduces excitement and calms the person
➢ A drug that reduces excitement, calms the patient (without inducing sleep)
➢ Sedatives in therapeutic doses are anxiolytic agents
➢ Most sedatives in larger doses produce hypnosis (trans like state in which
subject becomes passive and highly suggestible)
WHO Guideline & Stability Protocols for Liquid Dosage FormsAnindya Jana
These guidelines seek to exemplify the core stability data package required for registration of active pharmaceutical ingredient (APIs) & finished pharmaceutical protocols (FPPs), replacing the previous WHO guidelines in this area. However, alternative approaches can be used when they are scientifically justified. Further guidelines can be found in International Conference on Harmonisation (ICH) guidelines and in the who guidelines on the active pharmaceutical ingredient master file procedure.
Experimental Design presentation slides for level 400.pptxSethKoomson1
for agriculture research bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbb
Similar to Bracketing and Matrixing Methods for Stability analysis (20)
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Bracketing and Matrixing Methods for Stability analysis
1. BRACKETING AND MATRIXING DESIGNS
FOR STABILITY TESTING OF NEW DRUG
SUBSTANCES AND PRODUCTS
(Q1D)
Presented By
T V Sarath Chandra
M Pharm I Year SEM I
Regd. No. 170609008
1
Guided by
Dr. Swapnil J D
Assistant Professor
DEPARTMENT OF PHARMACEUTICAL QUALITY ASSURANCE
MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES
MANIPAL UNIVERSITY
3. ICH
International Conference of Harmonisation of technical requirements for
registration of pharmaceuticals for human use.
ICH Topics are divided into four categories .
3
4. 4
1. Q1A (R2)-Stability testing for new drug substances and products.
2. Q1B - Stability testing: Photo stability testing of new drug substances and products.
3. Q1C - Stability testing for new dosage forms
4. Q1D - Bracketing and Matrixing designs for stability testing of new drug
substances and products.
5. Q1E - Evaluation of stability data
6. Q1F- Stability data package for Registration applications in Climatic zones III and
IV
Q1 - STABILITY
5. Introduction
These are reduced designs in which all samples are not tested at all time points.
Alternatively used when multiple design factors are involved.
Certain assumptions should be made and justified.
Potential risk should be considered before assuming the shorter retest period
and shelf life.
A change from full to reduced test design should be considered, if the
justification is done and principles of both the designs are followed.
During the test study, once the design is changed from the full to reduced it
should be carried out through the remaining study.
5
6. Applicability of the Reduced designs
It can be applied for drug products, but additional justification should be done for
some complex substances which have potential drug-device reaction.
For drug substances, bracketing is not applicable and matrixing is of limited use.
Whether bracketing or matrixing should be done, decided as per the conditions.
Data variability and product stability shown by the supporting data should be
considered for the application of matrixing design.
Careful consideration and scientific justification should be there in selection of
designs.
6
7. Bracketing
In this the samples in the extremes of design factors are only tested at all time
points.
It assumes that the stability of the intermediates is represented by the stability of
the extremes tested.
The use of this design is inappropriate if the selected samples are not the
extremes.
Design factors:
These are variables which should be evaluated for their effect on stability.
They are
1. Strength
2. Container size or fill
7
8. Strength
Applied for multiple strengths and closely related formulations.
Examples:
a) Capsules - different fill plug sizes and strengths, made up of same
powder blend.
b) Tablets - different strengths manufactured with compressing
varying amounts of same granulation.
c) Oral solutions - different strengths which may differ in minor
excipients (colorants, flavourings)
If different excipients are used among strengths, bracketing should not be
applied.
8
9. Container size or fills
Either fill size or container size should be vary and other should be constant.
If both are varying, the smallest and largest are not considered as the extremes of
the packaging operations.
In selecting the extremes, compare the characters carefully because it may effect
the stability of the product.
The characters include container wall thickness, surface to volume ratio, oxygen
permeation rate per dosage unit, closure geometry.
It is applied for the same container having different closures with justification.
9
10. Design consideration and Potential Risk
During the study, if one of the extreme is known to be no longer in the
market, then design is made for supporting the intermediates.
Retest period and shelf life should be assessed before applying this design.
If the stabilities of both the extremes are different, then the stability of the
intermediate will be considered as not more than the least stable extreme.
The shelf lives of the intermediates will be less than the shelf life of the least
stable extreme.
10
11. Design Example
Table 1
Strength 50mg 75mg 100mg
Batch 1 2 3 1 2 3 1 2 3
Container
size
15ml T T T T T T
100ml
500ml T T T T T T
11
12. Matrixing
It is the stability schedule in which selected samples for all combinations are
tested at a time point.
At subsequent time point, another set of samples of all combinations are tested.
This design assumes that the stability of each set of samples represents the
stability of the remaining samples at a given point.
The differences in the same drug sample are different strengths, different batches,
different sizes of the same container closure system.
When secondary packaging system contributes to the stability of the system, then
packaging materials should be tested.
12
13. Design factors
This design can be applied for different strengths of identical or closely related
substances. Examples are
a) Capsules - different fill plug sizes and strengths, made up of same powder
blend.
b) Tablets - different strengths and compressed with varying amounts of
same granulation.
c) Oral solutions - different strengths which may differ in minor excipients.
d) Different batches made by same process and same equipment.
Justification should be done based on supporting data.
13
14. Design Considerations
In this design, each sample should be tested at intended time points and should be
tested at last time point before the submission.
Because it is difficult to test at all time points as in full test, some time points are
matrixed.
It should be tested for first and last time points for selected factors, but for some
factors intermediate time points should also be tested.
For accelerated or intermediate storage condition testing, atleast three points
should be tested.
14
15. Design Example
Time points (months) 0 3 6 9 12 18 24 36
S
T
R
E
N
G
T
H
S1 Batch 1 T T T T T T
Batch 2 T T T T T T
Batch 3 T T T T T
S2 Batch 1 T T T T T
Batch 2 T T T T T T
Batch 3 T T T T T
15
Table 2: Examples of Matrixing Designs on Time Points for a product with two strengths
One half reduction
16. Time points (months) 0 3 6 9 12 18 24 36
S
T
R
E
N
G
T
H
S1 Batch 1 T T T T T T
Batch 2 T T T T T T
Batch 3 T T T T T T T
S2 Batch 1 T T T T T T T
Batch 2 T T T T T T
Batch 3 T T T T T T
16
One third reduction
17. The one half reduction in which one in two time points is eliminated from
testing.
The one third reduction in which one in three time points is eliminated
from testing.
These examples include the full testing for the initial, final and 12 month
time period points.
In one half reduction, the time points are reduced less than the one half
(24/48) that is actually (15/48).
In one third reduction, the time points are reduced less than the one third
(16/48) that is actually (10/48).
17
18. Applicability and Degree of reduction
The following should be followed when matrixing is applied:
• knowledge of data variability
• availability of supporting data
• stability differences in the product within a factor or among factors
• number of factor combinations in the study
In general matrixing is done when the appropriate supporting data indicate
appropriate product stability.
If the variability in the supporting data is less and moderate matrixing can be
done.
If the variability is high matrixing cannot be done.
contd…
18
19. The matrixing design can be justified with respect to its power to detect
differences among factors of degradation and its precision in shelf life estimation.
If the design is applicable, the degree of reduction depends on the number of
factors involved.
The more the factors involved, the more the degree of the reduction.
Any design should have the ability to calculate the shelf life of a product
appropriately.
19
20. Potential Risk
Due to the insufficient data collected for the testing, the matrixing design may get
lesser shelf life than the shelf life got from the full test design.
That matrixing design has lesser efficiency to detect certain interaction effects
leading to incorrect pooling of data.
If testing of factor combinations is reduced, the tested factor combinations cannot
give sufficient data for finding the shelf life.
20
21. The design which have reduction in time points only have the ability of
establishing of shelf life as in full test design.
It exists because the full testing of all the samples is done at initial and
final time point before the submission.
Data Evaluation
The data collected from the reduced design should be treated in the same
manner as collected from the full test design by using statistical
applications.
21
22. CONCLUSION
The reduced test designs are used for the testing the stability in lesser time than
the full test design by considering some risks.
Bracketing design in which extremes are tested and Matrixing design in which
selected samples are tested.
Bracketing is mainly used to pursue a trend initially in pre clinical studies and
clinical trials. Matrixing is used to confirm a prediction of the stability
information.
The reduced designs should be used after the proper justification and scientific
consideration.
They may not get precise shelf life values as the full test design.
22
23. Reference
BRACKETING AND MATRIXING DESIGNS FOR STABILITY
TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS Q1D :
ICH Harmonised Tripartite Guideline, current step 4 version, 7 February
2002, page no: 1-7
23